Revance Therapeutics (RVNC)
(Delayed Data from NSDQ)
$6.57 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.58 +0.01 (0.15%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for Revance Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -323.99 | -356.42 | -281.31 | -282.09 | -159.43 |
Depreciation/Amortization & Depletion | 102.83 | 38.85 | 21.19 | 19.55 | 0.27 |
Net Change from Assets/Liabilities | -43.88 | 0.67 | -4.77 | 39.97 | 34.27 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 48.46 | 123.36 | 43.35 | 44.06 | 18.72 |
Net Cash From Operating Activities | -216.58 | -193.55 | -221.54 | -178.50 | -106.16 |
Property & Equipment | -6.89 | -3.21 | -10.38 | -4.10 | -3.23 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | -0.82 | 0.00 |
Investments | 121.51 | -115.79 | -11.59 | 17.17 | -14.36 |
Other Investing Activities | -4.88 | -19.80 | -7.70 | -0.12 | 0.00 |
Net Cash from Investing Activities | 109.74 | -138.80 | -29.67 | 12.13 | -17.59 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 115.47 | 252.83 | 38.39 | 90.84 | 223.78 |
Issuance (Repayment) of Debt | 30.16 | 87.05 | 0.00 | 287.50 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -9.07 | -8.19 | -8.53 | -46.86 | -2.12 |
Net Cash from Financing Activities | 136.57 | 331.69 | 29.87 | 331.48 | 221.66 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 29.73 | -0.65 | -221.33 | 165.11 | 97.90 |
Cash at Beginning of Period | 115.02 | 115.67 | 337.00 | 171.89 | 73.99 |
Cash at End of Period | 144.75 | 115.02 | 115.67 | 337.00 | 171.89 |
Diluted Net EPS | -3.83 | -4.90 | -4.17 | -4.86 | -3.67 |
Fiscal Year End for Revance Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -90.63 | -53.15 | -323.99 | -268.29 | -127.11 |
Depreciation/Amortization & Depletion | 1.73 | 1.38 | 102.83 | 101.96 | 7.99 |
Net Change from Assets/Liabilities | -33.99 | -23.14 | -43.88 | -47.06 | -32.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 15.82 | 8.97 | 48.46 | 39.54 | 29.18 |
Net Cash From Operating Activities | -107.07 | -65.94 | -216.58 | -173.84 | -122.88 |
Property & Equipment | -2.18 | -1.71 | -6.89 | -5.11 | -0.60 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -31.15 | -26.54 | 121.51 | 115.86 | 56.39 |
Other Investing Activities | -5.26 | -3.46 | -4.88 | -3.38 | 0.00 |
Net Cash from Investing Activities | -38.60 | -31.71 | 109.74 | 107.37 | 55.78 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 98.20 | 97.65 | 115.47 | 114.21 | 114.15 |
Issuance (Repayment) of Debt | -8.12 | -4.23 | 30.16 | 32.90 | -8.90 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.67 | -0.59 | -9.07 | -8.92 | -4.52 |
Net Cash from Financing Activities | 89.41 | 92.83 | 136.57 | 138.20 | 100.74 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -56.25 | -4.82 | 29.73 | 71.72 | 33.64 |
Cash at Beginning of Period | 144.75 | 144.75 | 115.02 | 115.02 | 115.02 |
Cash at End of Period | 88.50 | 139.93 | 144.75 | 186.74 | 148.66 |
Diluted Net EPS | -0.36 | -0.58 | -0.66 | -1.63 | -0.80 |